G1 Therapeutics to Report Myelopreservation Data from Randomized Phase 2 Trial of Trilaciclib/Chemotherapy/Tecentriq® in Small Cell Lung Cancer in Fourth Quarter 2018
September 17, 2018 06:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Sept. 17, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it is expediting analyses of...
G1 Therapeutics Announces Appointment of Garry Nicholson to Board of Directors
September 13, 2018 07:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Sept. 13, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Garry Nicholson has been appointed to...
G1 Therapeutics to Present at H.C. Wainwright Investment Conference on September 5, 2018
August 28, 2018 06:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Aug. 28, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Buck Phillips, Chief Financial Officer...
G1 Therapeutics Provides Second Quarter 2018 Corporate and Financial Update
August 08, 2018 16:01 ET
|
G1 Therapeutics
Presenting additional data from randomized Phase 2 trilaciclib/chemotherapy trial in first-line small cell lung cancer at ESMO 2018 in October Initiated Phase 2a enrollment of lerociclib (G1T38) in...
G1 Therapeutics to Present at Wedbush PacGrow Healthcare Conference on August 14, 2018
August 07, 2018 06:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Medical Officer Raj Malik, M.D.,...
G1 Therapeutics to Provide Second Quarter 2018 Corporate and Financial Update on August 8, 2018
August 01, 2018 06:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference...
G1 Therapeutics Expands Executive Leadership Team with Appointment of John Demaree as Chief Commercial Officer and Stillman Hanson as General Counsel
July 09, 2018 07:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., July 09, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced appointments for two newly created executive...
G1 Therapeutics Announces Appointment of New Members to the Board of Directors
June 08, 2018 07:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., June 08, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that Cynthia Schwalm and Willie Deese have...
G1 Therapeutics Presents Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
June 02, 2018 09:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., June 02, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that preliminary data from its Phase 1b/2a...
G1 Therapeutics to Present Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
May 16, 2018 17:07 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., May 16, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that preliminary data from its Phase 1b/2a...